Abstract
Hepatitis C virus (HCV) infects more than 170 million people worldwide and is the main cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Although the newly developed direct-acting antivirals (DAAs) have transformed the treatment of HCV infection, controlling HCV infection on a global scale remains a challenge because of the high cost, low resistance barrier of DAAs and lack of HCV vaccine. The host immune responses associated with HCV infection, especially HCV-specific T cellular immunity, determine the outcome of HCV infection: either acute or chronic infection. It is important to fully interpret the immunopathogenesis of HCV infection and consequently to exploit effective strategies to eliminate HCV. Here, we review the current progress in HCV immunology, which will deepen our understanding of the spectrum of HCV infection and immunity in humans.
Similar content being viewed by others
References
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135
Rehermann B. HCV in 2015: advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol 2016;13:70–72
Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S294–S302
Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362
Khan AG, Whidby J, Miller MT, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381–384
Yang Z, Wang X, Chi X, et al. Neglected but important role of apolipoprotein E exchange in hepatitis C virus infection. J Virol 2016;90:9632–9643
Fauvelle C, Felmlee DJ, Crochet E, et al. Apolipoprotein E mediates evasion from hepatitis C virus neutralizing antibodies. Gastroenterology 2016;150:206–217
Hiet MS, Bauhofer O, Zayas M, et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol 2015;63:829–837
Shata MT, Anthony DD, Carlson NL, et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepatol 2002;9(6):400–410
Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191(9):1499–1512
Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016;16:509–523
Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013;207(Suppl 1):S7–S12
Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6(5):578–582
Veerapu NS, Raghuraman S, Liang TJ, et al. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011;140(2):676–685
Penna A, Pilli M, Zerbini A, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007;45(3):588–601
Abdel-hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol 2014;5:274
Wiegand J, Jäckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004;40(1):98–107
Zibert A, Meisel H, Kraas W, et al. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997;25(5):1245–1249
Swann RE, Mandalou P, Robinson MW, et al. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. J Viral Hepatol 2016;23:873–880
Ahlenstiel G, Martin MP, Gao X, et al. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017–1026
Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol 2016;88:185–195
Wandrer F, Falk CS, John K, et al. Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C virus infection. J Infect Dis 2016;213:746–754
Lau DT, Negash A, Chen J, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013;144(2):402–413
Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010;53:424–430
Mondelli MU. Direct-acting antivirals cure innate immunity in chronic hepatitis C. Gastroenterology 2015;149:25–28
Yin W, Tong S, Zhang Q, et al. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep 2016;6:26296
Barathan M, Mohamed R, Vadivelu J, et al. Peripheral loss of CD8(+)CD161(++)TCRVα7.2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur J Clin Invest 2016;46:170–180
Zhang Y, El-Far M, Dupuy FP, et al. HCV RNA activates APCs via TLR7/TLR8 while virus selectively stimulates macrophages without inducing antiviral responses. Sci Rep 2016;6:29447
Raghuraman S, Park H, Osburn WO, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T cell exhaustion. J Infect Dis 2012;205:763–771
Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013;3(4):461–467
Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog 2015;11:e1005177
Hartling HJ, Ballegaard VC, Nielsen NS, et al. Immune regulation in chronic hepatitis C virus infection. Scand J Gastroenterol 2016;51:1387–1397
Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81(6):2545–2553
Burke Schinkel SC, Carrasco-Medina L, Cooper CL, et al. Generalized liver- and blood-derived CD8+ T-cell impairment in response to cytokines in chronic hepatitis C virus infection. PLoS One 2016;11:e0157055
Bhattarai N, McLinden JH, Xiang J, et al. Conserved motifs within hepatitis C virus envelope (E2) RNA and protein independently inhibit T cell activation. PLoS Pathog 2015;11:e1005183
Chen JH, Perry CJ, Tsui YC, et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med 2015;21:327–334
Pelletier S, Bedard N, Said E, et al. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol 2013;87(12):6769–6781
Zabaleta A, Riezu-Boj JI, Larrea E, et al. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. J Med Virol 2016;88(5):843–851
Liang CC, Liu CH, Lin YL, et al. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83(7):1212–1220
Rana D, Chawla YK, Duseja A, et al. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int 2012;32(7):1128–1137
Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance. PLoS One 2014;9(7):e102605
Crosignani A, Riva A, Della BS. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016;22(4):1393–1404
Tu Z, Zhang P, Li H, et al. Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol 2013;284(1–2):98–103
Sachdeva M, Chawla YK, Arora SK. Dendritic cells: the warriors upfront-turned defunct in chronic hepatitis C infection. World J Hepatol 2015;7(19):2202–2208
Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012;3(7):610–620
Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 2010;184(6):3134–3144
Ryan EJ, Stevenson NJ, Hegarty JE, et al. Chronic hepatitis C infection blocks the ability of dendritic cells to secrete IFN-alpha and stimulate T-cell proliferation. J Viral Hepatol 2011;18(12):840–851
Zhao L, Tyrrell DL. Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection. Viral Immunol 2013;26(1):25–39
Zeng QL, Yang B, Sun HQ, et al. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8+ T cells in chronic hepatitis C patients. Mol Cells 2014;37(1):66–73
Ren JP, Zhao J, Dai J, et al. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the STAT3 pathway. Immunology 2016;148:377–386
Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302(5645):659–662
Raziorrouh B, Ulsenheimer A, Schraut W, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 2011;141(4):1422–1431
Kared H, Fabre T, Bedard N, et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013;9:e1003422
Mele D, Mantovani S, Oliviero B, et al. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Res 2017;137:108–111
Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009;199(6):819–828
Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006;45:183–191
Chang Q, Wang YK, Zhao Q, et al. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol 2012;27:273–278
Neuman MG, Sha K, Esquerra R, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008;53:1468–1487
Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in vivo resistance to interferon α treatment. Gut 2014;63(3):515–524
Kang W, Shin EC. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J 2011;52:871–878
Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015;12:387–400
Ren JP, Ying RS, Cheng YQ, et al. HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepatol 2016;23:755–766
Veerapu NS, Park SH, Tully DC, et al. Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 2014;124(8):3469–3478
Dessouki O, Kamiya Y, Nagahama H, et al. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem Biophys Res Commun 2010;393(2):331–337
Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011;141(4):1231–1239
Larrubia JR, Moreno-Cubero E, Miquel J, et al. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015;21:3480–3491
Zhang C, Hua R, Cui Y, et al. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. PLoS One 2017;12(2):e0171217
Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015;149:190–200.e2
Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352–3363
Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014;61:538–543
Burchill MA, Golden-Mason L, Wind-Rotolo M, et al. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J Viral Hepatol 2015;22(12):983–991
Hofmann M, Thimme R. MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection. Eur J Immunol 2016;46(9):2099–2102
Hengst J, Falk CS, Schlaphoff V, et al. DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 2016;214(12):1965–1974
Callendret B, Eccleston HB, Satterfield W, et al. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral. Hepatology 2016;63:1442–1454
Shrivastava S, Wilson E, Poonia B, et al. Augmentation of HCV specific immunity and sustained virological response (SVR). J Viral Hepatol 2017. doi:10.1111/jvh.12702
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Yuanyuan Li has received research Grants from the National Natural Science Foundation of China (81601731). Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang and Fu-Sheng Wang declare no conflict of interests.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Shi, J., Li, Y., Chang, W. et al. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int 11, 374–383 (2017). https://doi.org/10.1007/s12072-017-9805-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-017-9805-2